{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T11:27:12Z","timestamp":1786793232694,"version":"build-2736575974"},"reference-count":36,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100005565","name":"Johnson & Johnson Innovative Medicine","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psoriasis and Psoriatic Arthritis\u00ae"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The first phase of the Psoriasis Longitudinal Assessment and Registry (PSOLAR) provided safety, demographic, and other outcomes data from &gt;12,000 patients (&gt;75,000 patient-years) eligible to receive biologics for psoriasis. In 2018, PSOLAR enrollment criteria were updated to specifically include patients receiving either guselkumab or an interleukin-17 inhibitor (IL-17i).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Baseline characteristics are described for patients included in PSOLAR after adoption of Protocol Amendment 6 (March 26, 2018), which updated enrollment criteria to include patients exposed to guselkumab or an IL-17i.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      As of July 12, 2025, 3501 patients (guselkumab, n = 2213; IL-17i, n = 1288) were enrolled at sites in 17 countries. Baseline characteristics were generally balanced between the guselkumab and IL-17i cohorts. The majority of patients were male (59.9%), white (74.3%), and overweight\/obese (78.5%; mean [SD] BMI = 30.2 [7.2] kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ). Mean (SD) age was 50.3 (13.9) years. On average, patients had longstanding psoriasis at baseline (mean [SD] duration of psoriasis = 19.0 [13.7] years; mean [SD] body surface area = 8.6% [12.7]). Most patients reported current or prior history of alcohol use (77.3%) and smoking (54.1%). Prior to enrollment, most patients (76.9%) reported exposure to \u22651 biologic. Self-reported psoriatic arthritis was less common in the guselkumab vs the IL-17i group (25.0% vs 38.1%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with psoriasis treated with guselkumab or an IL-17i in this real-world cohort had similar baseline characteristics, although psoriatic arthritis was more common in the IL-17i group. Findings from PSOLAR may help clinicians better understand characteristics of patients who may be prescribed guselkumab or an IL-17i for psoriasis in a real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinicaltrials.gov Identifier<\/jats:title>\n                    <jats:p>NCT00508547.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/24755303261477021","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T07:48:21Z","timestamp":1786520901000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Characteristics of Real-World Patients with Psoriasis Receiving Guselkumab or Interleukin-17 Inhibitors: Data from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8394-2057","authenticated-orcid":false,"given":"Bruce","family":"Strober","sequence":"first","affiliation":[{"name":"Department of Dermatology, Yale University School of Medicine"},{"name":"Central Connecticut Dermatology Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Augustin","sequence":"additional","affiliation":[{"name":"Director and Chair, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3743-135X","authenticated-orcid":false,"given":"Yayoi","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Teikyo University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Parnell Lafferty","sequence":"additional","affiliation":[{"name":"Johnson & Johnson"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yevgeniy","family":"Krol","sequence":"additional","affiliation":[{"name":"Johnson & Johnson"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Skobelev","sequence":"additional","affiliation":[{"name":"Johnson & Johnson"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fowzia","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Johnson & Johnson"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Fakharzadeh","sequence":"additional","affiliation":[{"name":"Johnson & Johnson"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Gniadecki","sequence":"additional","affiliation":[{"name":"University of Alberta"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-025-00630-5"},{"issue":"10","key":"e_1_3_6_3_2","first-page":"1210","article-title":"PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents","volume":"11","author":"Papp KA","year":"2012","unstructured":"Papp KA, Strober B, Augustin M, Calabro S, Londhe A, Chevrier M, PSOLAR investigators and Steering Committee. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J Drugs Dermatol. 2012;11(10):1210-1217.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13013"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.0718"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.07.013"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.08.032"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.08.051"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13611"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16737"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-018-0388-z"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2022.02.013"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/24755303221099848"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08183.x"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109997"},{"issue":"3","key":"e_1_3_6_16_2","first-page":"469","article-title":"Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the psoriasis epidemiology screening tool (PEST) questionnaire","volume":"27","author":"Ibrahim GH","year":"2009","unstructured":"Ibrahim GH, Buch MH, Lawson C, Waxman R, Helliwell PS. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the psoriasis epidemiology screening tool (PEST) questionnaire. Clin Exp Rheumatol. 2009;27(3):469-474.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205207"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.38995"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1833"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-018-8702-3"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.39685"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00776-6"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.08.006"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301668"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.298"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2155"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1329511"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1124628"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad115"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.6216"},{"key":"e_1_3_6_32_2","volume-title":"Package Insert","author":"TREMFYA","year":"2025","unstructured":"TREMFYA. Package Insert. Janssen Biotech, Inc.; 2025."},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2025.102583"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70167"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00034-6"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.058"},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3386"}],"container-title":["Journal of Psoriasis and Psoriatic Arthritis\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24755303261477021","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/24755303261477021","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24755303261477021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T11:16:23Z","timestamp":1786792583000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/24755303261477021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":36,"alternative-id":["10.1177\/24755303261477021"],"URL":"https:\/\/doi.org\/10.1177\/24755303261477021","relation":{},"ISSN":["2475-5303","2475-5311"],"issn-type":[{"value":"2475-5303","type":"print"},{"value":"2475-5311","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"article-number":"24755303261477021"}}